{"filing":{"accession_number":"0001104659-26-077892","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tm2618527d2_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926077892/tm2618527d2_6k.htm"},"events":[{"id":14073,"run_id":12512,"accession_number":"0001104659-26-077892","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ProQR announced the pricing of an underwritten registered direct offering of 27.6 million ordinary shares at $1.81 per share for ~$50 million gross proceeds, plus a concurrent private placement of 5.1 million shares to Eli Lilly for ~$9.2 million. This is a material equity issuance that dilutes existing shareholders and raises capital through unregistered (private placement) and registered direct offerings, fitting the dilutive_issuance category. The concurrent private placement to Lilly is explicitly noted as exempt from registration under Section 4(a)(2) of the Securities Act.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11404,"accession_number":"0001104659-26-077892","item_number":"EX-99.1","item_title":"tm2618527d2_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProQR announced the pricing of an underwritten registered direct offering of 27.6 million ordinary shares at $1.81 per share for ~$50 million gross proceeds, plus a concurrent private placement of 5.1 million shares to Eli Lilly for ~$9.2 million. This is a material equity issuance that dilutes existing shareholders and raises capital through unregistered (private placement) and registered direct offerings, fitting the dilutive_issuance category. The concurrent private placement to Lilly is explicitly noted as exempt from registration under Section 4(a)(2) of the Securities Act.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:06:11.100402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11404,"accession_number":"0001104659-26-077892","item_number":"EX-99.1","item_title":"tm2618527d2_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProQR announced the pricing of an underwritten registered direct offering of 27.6 million ordinary shares at $1.81 per share for ~$50 million gross proceeds, plus a concurrent private placement of 5.1 million shares to Eli Lilly for ~$9.2 million. This is a material equity issuance that dilutes existing shareholders and raises capital through unregistered (private placement) and registered direct offerings, fitting the dilutive_issuance category. The concurrent private placement to Lilly is explicitly noted as exempt from registration under Section 4(a)(2) of the Securities Act.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:06:11.100402+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-06-25"}]}